Skip to main content

Table 2 Antibiotic use over time: total consumption and parameters of the multiple linear regression model

From: Antimicrobial stewardship in high-risk febrile neutropenia patients

Antibiotics Intercept β0 [CI] Period 1 Period 2
Total β1 [CI] p-value Total β2 [CI] p-value
Aminoglycosides + 10.69 [− 44.67; + 66.05] 140 + 5.77 [− 11.18; + 22.71] 0.45 81 − 5.09 [− 16.90; + 6.71] 0.34
Glycopeptides + 142.54 [+ 71.56; + 213.51] 754 + 2.47 [− 19.26; + 24.19] 0.80 113 − 17.34 [− 32.48;− 2.21] 0.03
Carbapenems + 112.95 [− 100.10; + 325.99] 1187 + 41.78 [− 23.42; + 106.99] 0.17 331 − 47.73 [− 93.15;− 2.31] 0.04
Class 3 β-lactams + 39.00 [+ 6.48; + 71.51] 74 − 8.35 [− 18.30; + 1.60] 0.09 52 + 4.89 [− 2.05; + 11.82] 0.14
Class 4 β-lactams + 203.79 [+ 18.64; + 388.94] 1173 + 12.32 [− 44.34; + 68.98] 0.62 1642 + 2.49 [− 36.98; + 41.96] 0.89
Fluoroquinolones + 43.18 [− 101.31; + 187.68] 85 − 7.32 [− 51.55; + 36.90] 0.71 183 + 5.99 [− 24.81; + 36.80] 0.66
Daptomycine + Linezolide + 6.43 [− 33.54; + 46.40] 56 + 2.01 [− 10.22; + 14.25] 0.71 37 − 2.05 [− 10.57; + 6.47] 0.59
Cotrimoxazole + 32.75 [− 20.97; + 86.46] 286 + 7.70 [− 8.74; + 24.14] 0.30 86 − 9.48 [− 20.93; + 1.97] 0.09
All antibiotics + 1692.82 [+ 1235.32; + 2150.33] 6848 − 105.66 [− 245.67; + 34.36] 0.12 3473 − 19.91 [− 117.45; + 77.63] 0.64
  1. Total antibiotic consumption is expressed in defined daily dose per 1000 patient-days. Raw consumption of daptomycin was 35 DDD/1000 patient-days in both pre- and post-intervention periods. Raw consumption of linezolide was 21 DDD/1000 patient-days in the pre-intervention period and 2 DDD/1000 patient-days in the post-intervention period
  2. CI: 95% confidence interval; Class 3 β-lactams: third-generation cephalosporins or ureido/carboxy-penicillins; Class 4 β-lactams: piperacillin/tazobactam, fourth-generation cephalosporins or antipseudomonal third-generation cephalosporins